AG
CASC

Advisor Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Advisor Group’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-74
Closed – – 5199
2017
Q4 		$0 Buy
74
+63
+573% +$258 ﹤0.01% 5183
2017
Q3 		$0 Hold
11
– – ﹤0.01% 5065
2017
Q2 		$0 Hold
11
– – ﹤0.01% 5015
2017
Q1 		$0 Hold
11
– – ﹤0.01% 4905
2016
Q4 		$0 Sell
11
-417
-97% -$2.7K ﹤0.01% 4749
2016
Q3 		$4K Buy
428
+417
+3,791% +$2.96K ﹤0.01% 4032
2016
Q2 		$0 Buy
+11
New +$75 ﹤0.01% 4604

Advisor Group's CASC Position: Q1 2018 in Review

Advisor Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 74 shares.

Advisor Group first reported a position in CASC in Q2 2016 and held it in 7 quarters. The position peaked at $4K in Q3 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Advisor Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Advisor Group sold 74 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Advisor Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
  • Advisor Group's Cascadian Therapeutics, Inc. position peaked at $4K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Advisor Group's 13F filing for Q1 2018, filed 15 May 2018.